<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0018646"><a href="http://purl.obolibrary.org/obo/MONDO_0018646">MONDO:0018646</a></h3>
<p><strong>Label:</strong> sclerosing cholangitis (disease)</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0013433">MONDO:0013433</a> (primary sclerosing cholangitis),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_171">Orphanet:171</a>, <a href="http://purl.obolibrary.org/obo/OMIM_602114">OMIM:602114</a>, <a href="http://purl.obolibrary.org/obo/OMIM_613806">OMIM:613806</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0100575">HP:0100575</a> (Neoplasm of the gallbladder) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100871">HP:0100871</a> (Abnormality of the palm) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100869">HP:0100869</a> (Palmar telangiectasia) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100834">HP:0100834</a> (Neoplasm of the large intestine) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100831">HP:0100831</a> (Abnormality of vitamin K metabolism) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100763">HP:0100763</a> (Abnormality of the lymphatic system) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100651">HP:0100651</a> (Type I diabetes mellitus) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100646">HP:0100646</a> (Thyroiditis) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100626">HP:0100626</a> (Chronic hepatic failure) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100585">HP:0100585</a> (Telangiectasia of the skin) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100575">HP:0100575</a> (Neoplasm of the gallbladder) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100533">HP:0100533</a> (Inflammatory abnormality of the eye) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100514">HP:0100514</a> (Abnormality of vitamin E metabolism) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100513">HP:0100513</a> (Vitamin E deficiency) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030153">HP:0030153</a> (Cholangiocarcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100512">HP:0100512</a> (Vitamin D deficiency) 66.67%</li>
</ul>
</body>
</html>
